Partnerships

Global Health Partnership (EDCTP3)

Partnership website: https://www.globalhealth-edctp3.eu/

The partnership aims to deliver new solutions reducing the burden of infectious diseases in sub-Saharan Africa, and strengthen research capacities for preparedness and response against reemerging infectious diseases in sub-Saharan Africa and globally. Belgium is member of the EDCTP Association. EDCTP3 was launched in 2022.

The European & Developing Countries Clinical Trials Partnership (EDCTP) exists to accelerate the clinical development of new or improved health technologies for the identification, treatment and prevention of poverty-related and neglected infectious diseases, including (re-)emerging diseases.

The Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3) builds on the first and second EDCTP programmes and is a partnership between the EU and the EDCTP Association, whose members are several European and African countries.

The partnership will deliver new solutions for reducing the burden of infectious diseases in sub-Saharan Africa, and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and across the world.

Key figures

Total budget of Global Health EDCTP3 is 1.6 billon euro
The partnership includes 40 European & African countries

Participation Flanders

The following organisations based in Flanders are partner in ongoing EDCTP3 projects (2022 & 2023 work programme):

University of Antwerp in the projects 'SEMA ReACT', 'SNIP-AFRICA', 'GenPath Africa' & 'PROTECT'
Institute for Tropical Medicine (ITM) in the project 'STROGHAT'
Ghent University in the project 'NeuroSolve' & 'ODIN'
Flemish Institute for Biotechnology (VIB) in the project 'ODIN'
Janssen Pharmaceutica nv in the project 'CTCAN'

Past & current calls for proposals

Since it took off in 2022, EDCTP has launched several calls of proposals. Information on the latest calls for proposals can be found in the 2024 annual work programme. Any further information can be found on the EDCTP3 Calls for proposals webpage.

All EDCTP3 calls for proposals are also published on the European Commission’s Funding and Tender opportunities portal.

Key documents

Draft partnership proposal (August 2020)
Strategic Research and Innovation Agenda of the GH EDCTP3 (January 2022)
Policy context: Global health - EDCTP

Contact

Partnership: EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu

What are partnerships?

Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.

More detailed info Overview of partnerships

How to use partnerships?

orientation
Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points.
networking
Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents.
ecosystem analysis
Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain.
steering the agenda
Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

Read the full article or Check out the other testimonials

Funding programmes

Content